Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AP301 PD study on urinary phosphorus excretion in healthy volunteers
NCT06100627Phase 1Completed
- Sponsor
- Alebund Pharmaceuticals
- Start
- Jan 2024
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of AP301 in hyperphosphatemia (4 arms), sponsored by Alebund Pharmaceuticals. Primary endpoints: Urinary phosphorus excretion during AP301 administration, Effect of AP301 on urinary phosphorus excretion and 3 more. Started Jan 2024; status: completed.
02
Drugs
AP301
03
Conditions
hyperphosphatemia
Beyond the preview
Go deeper on NCT06100627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06100627.